Myeloproliferative syndromes and the associated risk of coronary artery disease

Apar Kishor P Ganti, Anil Potti, Vijay Kishore Koka, Hassan Pervez, Syed A. Mehdi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction: Of the major myeloproliferative syndromes (MPS) [polycythemia vera (PV), essential thrombocythemia (ET), chronic myeloid leukemia (CML) and myelofibrosis (MF)], PV and ET are reported to be associated with increased thrombotic complications. However, the relationship between these myeloproliferative syndromes and coronary artery disease (CAD) is unclear. Methods: We performed a retrospective chart review to evaluate the prevalence of CAD in patients with diagnosed with MPS between 1991 and 2001. Results: One hundred and eighty-one patients (100 males, 81 females) with a mean age of 72.5 years were included. Twenty-nine patients, 19 males and 10 females (16%, 95% CI: 12.0-24.0) had CAD. These included 6/53 (11.3%, 95% CI: 1.5-20.2) patients with CML, 1/26 (3.8%, 95% CI: -4.4 to 12.8) patients with PV, 5/30 (16.7%, 95% CI: 2.5-30.8) patients with ET, 3/7 (42.9%, 95% CI: 12.3-87.7) patients with MF and 14/65 (21.5%, 95% CI: 13.1-37.8) patients with co-existent MPS. Comparing the risk of CAD with CML as a baseline, MF had an OR of 8.2 (p<0.01, 95% CI: 1.7-39), PV-0.4 (p=0.4, 95% CI: 0.04-3.2), ET-1.6 (p=0.7, 95% CI: 0.43-6.2) and patients with co-existent MPS-2.8 (p=0.07, 95% CI: 0.91-8.6). However, after adjusting for age, sex, dyslipidemia, diabetes, hypertension and tobacco use, the difference in the prevalence of CAD between the various categories of MPS was not significant. Conclusion: Contrary to conventional belief, we did not find an increased prevalence of CAD in patients with either PV or ET. In fact, patients with MF had a significantly higher prevalence of CAD. However, this difference appears to be due to the increased age at diagnosis of MF. The conventional risk factors for CAD appear to be the major determinants of CAD among patients with MPS.

Original languageEnglish (US)
Pages (from-to)83-86
Number of pages4
JournalThrombosis Research
Volume110
Issue number2-3
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Coronary Artery Disease
Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tobacco Use
Dyslipidemias
Hypertension

Keywords

  • Coronary artery disease
  • Myeloproliferative syndromes
  • Polycythemia vera

ASJC Scopus subject areas

  • Hematology

Cite this

Myeloproliferative syndromes and the associated risk of coronary artery disease. / Ganti, Apar Kishor P; Potti, Anil; Koka, Vijay Kishore; Pervez, Hassan; Mehdi, Syed A.

In: Thrombosis Research, Vol. 110, No. 2-3, 01.05.2003, p. 83-86.

Research output: Contribution to journalArticle

Ganti, Apar Kishor P ; Potti, Anil ; Koka, Vijay Kishore ; Pervez, Hassan ; Mehdi, Syed A. / Myeloproliferative syndromes and the associated risk of coronary artery disease. In: Thrombosis Research. 2003 ; Vol. 110, No. 2-3. pp. 83-86.
@article{8e054e447879497c82237269793a2760,
title = "Myeloproliferative syndromes and the associated risk of coronary artery disease",
abstract = "Introduction: Of the major myeloproliferative syndromes (MPS) [polycythemia vera (PV), essential thrombocythemia (ET), chronic myeloid leukemia (CML) and myelofibrosis (MF)], PV and ET are reported to be associated with increased thrombotic complications. However, the relationship between these myeloproliferative syndromes and coronary artery disease (CAD) is unclear. Methods: We performed a retrospective chart review to evaluate the prevalence of CAD in patients with diagnosed with MPS between 1991 and 2001. Results: One hundred and eighty-one patients (100 males, 81 females) with a mean age of 72.5 years were included. Twenty-nine patients, 19 males and 10 females (16{\%}, 95{\%} CI: 12.0-24.0) had CAD. These included 6/53 (11.3{\%}, 95{\%} CI: 1.5-20.2) patients with CML, 1/26 (3.8{\%}, 95{\%} CI: -4.4 to 12.8) patients with PV, 5/30 (16.7{\%}, 95{\%} CI: 2.5-30.8) patients with ET, 3/7 (42.9{\%}, 95{\%} CI: 12.3-87.7) patients with MF and 14/65 (21.5{\%}, 95{\%} CI: 13.1-37.8) patients with co-existent MPS. Comparing the risk of CAD with CML as a baseline, MF had an OR of 8.2 (p<0.01, 95{\%} CI: 1.7-39), PV-0.4 (p=0.4, 95{\%} CI: 0.04-3.2), ET-1.6 (p=0.7, 95{\%} CI: 0.43-6.2) and patients with co-existent MPS-2.8 (p=0.07, 95{\%} CI: 0.91-8.6). However, after adjusting for age, sex, dyslipidemia, diabetes, hypertension and tobacco use, the difference in the prevalence of CAD between the various categories of MPS was not significant. Conclusion: Contrary to conventional belief, we did not find an increased prevalence of CAD in patients with either PV or ET. In fact, patients with MF had a significantly higher prevalence of CAD. However, this difference appears to be due to the increased age at diagnosis of MF. The conventional risk factors for CAD appear to be the major determinants of CAD among patients with MPS.",
keywords = "Coronary artery disease, Myeloproliferative syndromes, Polycythemia vera",
author = "Ganti, {Apar Kishor P} and Anil Potti and Koka, {Vijay Kishore} and Hassan Pervez and Mehdi, {Syed A.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1016/S0049-3848(03)00290-1",
language = "English (US)",
volume = "110",
pages = "83--86",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "2-3",

}

TY - JOUR

T1 - Myeloproliferative syndromes and the associated risk of coronary artery disease

AU - Ganti, Apar Kishor P

AU - Potti, Anil

AU - Koka, Vijay Kishore

AU - Pervez, Hassan

AU - Mehdi, Syed A.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Introduction: Of the major myeloproliferative syndromes (MPS) [polycythemia vera (PV), essential thrombocythemia (ET), chronic myeloid leukemia (CML) and myelofibrosis (MF)], PV and ET are reported to be associated with increased thrombotic complications. However, the relationship between these myeloproliferative syndromes and coronary artery disease (CAD) is unclear. Methods: We performed a retrospective chart review to evaluate the prevalence of CAD in patients with diagnosed with MPS between 1991 and 2001. Results: One hundred and eighty-one patients (100 males, 81 females) with a mean age of 72.5 years were included. Twenty-nine patients, 19 males and 10 females (16%, 95% CI: 12.0-24.0) had CAD. These included 6/53 (11.3%, 95% CI: 1.5-20.2) patients with CML, 1/26 (3.8%, 95% CI: -4.4 to 12.8) patients with PV, 5/30 (16.7%, 95% CI: 2.5-30.8) patients with ET, 3/7 (42.9%, 95% CI: 12.3-87.7) patients with MF and 14/65 (21.5%, 95% CI: 13.1-37.8) patients with co-existent MPS. Comparing the risk of CAD with CML as a baseline, MF had an OR of 8.2 (p<0.01, 95% CI: 1.7-39), PV-0.4 (p=0.4, 95% CI: 0.04-3.2), ET-1.6 (p=0.7, 95% CI: 0.43-6.2) and patients with co-existent MPS-2.8 (p=0.07, 95% CI: 0.91-8.6). However, after adjusting for age, sex, dyslipidemia, diabetes, hypertension and tobacco use, the difference in the prevalence of CAD between the various categories of MPS was not significant. Conclusion: Contrary to conventional belief, we did not find an increased prevalence of CAD in patients with either PV or ET. In fact, patients with MF had a significantly higher prevalence of CAD. However, this difference appears to be due to the increased age at diagnosis of MF. The conventional risk factors for CAD appear to be the major determinants of CAD among patients with MPS.

AB - Introduction: Of the major myeloproliferative syndromes (MPS) [polycythemia vera (PV), essential thrombocythemia (ET), chronic myeloid leukemia (CML) and myelofibrosis (MF)], PV and ET are reported to be associated with increased thrombotic complications. However, the relationship between these myeloproliferative syndromes and coronary artery disease (CAD) is unclear. Methods: We performed a retrospective chart review to evaluate the prevalence of CAD in patients with diagnosed with MPS between 1991 and 2001. Results: One hundred and eighty-one patients (100 males, 81 females) with a mean age of 72.5 years were included. Twenty-nine patients, 19 males and 10 females (16%, 95% CI: 12.0-24.0) had CAD. These included 6/53 (11.3%, 95% CI: 1.5-20.2) patients with CML, 1/26 (3.8%, 95% CI: -4.4 to 12.8) patients with PV, 5/30 (16.7%, 95% CI: 2.5-30.8) patients with ET, 3/7 (42.9%, 95% CI: 12.3-87.7) patients with MF and 14/65 (21.5%, 95% CI: 13.1-37.8) patients with co-existent MPS. Comparing the risk of CAD with CML as a baseline, MF had an OR of 8.2 (p<0.01, 95% CI: 1.7-39), PV-0.4 (p=0.4, 95% CI: 0.04-3.2), ET-1.6 (p=0.7, 95% CI: 0.43-6.2) and patients with co-existent MPS-2.8 (p=0.07, 95% CI: 0.91-8.6). However, after adjusting for age, sex, dyslipidemia, diabetes, hypertension and tobacco use, the difference in the prevalence of CAD between the various categories of MPS was not significant. Conclusion: Contrary to conventional belief, we did not find an increased prevalence of CAD in patients with either PV or ET. In fact, patients with MF had a significantly higher prevalence of CAD. However, this difference appears to be due to the increased age at diagnosis of MF. The conventional risk factors for CAD appear to be the major determinants of CAD among patients with MPS.

KW - Coronary artery disease

KW - Myeloproliferative syndromes

KW - Polycythemia vera

UR - http://www.scopus.com/inward/record.url?scp=0142258729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142258729&partnerID=8YFLogxK

U2 - 10.1016/S0049-3848(03)00290-1

DO - 10.1016/S0049-3848(03)00290-1

M3 - Article

VL - 110

SP - 83

EP - 86

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 2-3

ER -